cll-1.car t cells
Cell therapyexperimental
Clinical trial activity
4 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2020 (NCT04219163)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- C-type lectin domain family 12 member AImmunity, passive
immunity, passive - cll1
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07201727 | Early Phase 1 (Phase 1) | Sep 30, 2025 | China Academy of Chinese Medical Sciences |
| NCT06917105 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2025 | Government of China, Huazhong University of Science and Technology |
| NCT05252572 | Early Phase 1 (Phase 1) | Feb 28, 2022 | Yake Biotechnology Ltd., Zhejiang University |
| NCT04219163 | Phase 1 | Apr 1, 2020 | Baylor University, Methodist Cancer Center, Houston, Texas |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Baylor University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| China Academy of Chinese Medical Sciences | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Government of China | Government | 1 | 0 | 1 | 2025 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Methodist Cancer Center, Houston, Texas | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Yake Biotechnology Ltd. | Government | 1 | 0 | 1 | 2022 |
| Zhejiang University | Academic/Hospital | 1 | 1 | 1 | 2022 |
7 organizations
Page 1 / 1